325855-74-1

Usage

Uses

Used in Pharmaceutical Industry:
5-Chloro-6'-Methyl-3-[4-(Methylsulfonyl)phenyl]-2,3'-bipyridine 1'-Oxide is used as an impurity in the manufacturing process of Etoricoxib (E934100). Its presence is monitored and controlled to ensure the quality and safety of the final pharmaceutical product.

Upstream product

• 202409-33-4 etoricoxib 
• 221615-75-4 1-(6-methyl-3-pyridinyl)-2-[4-(methylsulfonyl)phenyl]ethanone 

Downstream Products

• 349536-41-0 6'-Hydroxymethyletoricoxib 

Relevant academic research and scientific papers

A general [3 + 2 + 1] annulation strategy for the preparation of pyridine N-oxides

equation presented Stabilized ketone, aldehyde, and ester enolates react with vinamidinium hexafluorophosphate salts and hydroxylamine hydrochloride to give access to the corresponding pyridine N-oxides. The annulation reactions proceed in good to excelle

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)

Characterization of the metabolites of the COX-2 inhibitor etoricoxib (MK-0663 and L-791, 456) produced in vitro indicate formation of an N-oxide pyridine and hydroxymethyl pyridine that can further be glucuronidated or oxidized to an acid. Significant turnover is observed in human hepatocytes. Several CYPs are involved in the oxidative biotranformations and, from in vitro studies, etoricoxib is not a potent CYP3A4 inducer or inhibitor. Based on an in vitro whole blood assay, none of the metabolites of etoricoxib inhibits COX-1 or contributes significantly to the inhibition of COX-2.